Gene-Editing Cholesterol Cure?! Breakthrough Study Has Doctors Stunned!

Scientists are edging closer to a potentially groundbreaking, albeit still experimental, approach to tackling high cholesterol: Gene editing. The idea is enticing – a one-time fix to what is often a lifelong battle for millions. But don't throw away your statins just yet.

Gene-Editing Cholesterol Cure?! Breakthrough Study...

We all need some cholesterol, but too much "bad" LDL cholesterol is a major culprit in plaque buildup in arteries, setting the stage for heart attacks and strokes. And as we all know, cardiovascular disease remains the number one killer worldwide.

Many people manage their cholesterol with medications like statins, a mainstay of treatment. However, these drugs aren't always a perfect solution. Many patients struggle to reach their target cholesterol levels, and let's face it, sticking to any medication long-term can be tough, especially when side effects pop up. Diet and exercise are key, but they aren't always enough, either.

While diet certainly plays a role, the American Heart Association emphasizes that our liver is the primary cholesterol factory, and our genes heavily influence how that cholesterol is managed. Some folks inherit genes that practically guarantee high cholesterol, while others naturally have remarkably low levels throughout their lives, seemingly immune to heart disease. What gives?

Years ago, Dr. Kiran Musunuru, now at the University of Pennsylvania, made a fascinating observation. He discovered that some people with naturally low cholesterol had a mutation that essentially switched off the ANGPTL3 gene, leading to lower levels of both LDL cholesterol and triglycerides. Separately, researchers at UT Southwestern Medical Center found that similarly low LDL levels in others were linked to loss of function of the PCSK9 gene. That made researchers ask: Could we mimic this effect therapeutically?

"It's a natural experiment in what would happen if we actually changed the gene," explained Dr. Steven Nissen of the Cleveland Clinic, highlighting the significance of these genetic discoveries. Nissen, along with Laffin, oversaw an ANGPTL3 study funded by CRISPR Therapeutics. Think of it as nature providing a blueprint for potential therapies.

We already have injectable medications that target the proteins produced by the PCSK9 and ANGPTL3 genes in the liver, helping the body clear cholesterol. Now, the cutting edge involves using CRISPR, the Nobel Prize-winning gene-editing tool, to try and actually deactivate one of these genes in people at high risk from uncontrolled cholesterol. It is a huge jump from statins.

One study involved giving 15 adults a single infusion of microscopic particles carrying the CRISPR tool directly to the liver, targeting the ANGPTL3 gene within the liver cells. The results? Within a couple of weeks, those who received the highest dose experienced a significant 50% reduction in both LDL and triglyceride levels, reported Laffin and Nissen back in November. That is a remarkable shift.

Verve Therapeutics, a Boston-based company owned by Eli Lilly, had previously announced that its PCSK9-targeted editing infusion also reduced LDL cholesterol by about the same amount in a smaller study. It's early days, but the potential is definitely there.

These initial studies were conducted in places like Australia and the U.K. According to a Lilly spokesperson, U.S. study sites are now starting to open up. Dr. Nissen also mentioned that a follow-up study of CRISPR Therapeutics' approach is expected to begin later this year. It's an exciting area of research, but for now, if your doctor recommends cholesterol-lowering medication, stick with it. Gene editing for high cholesterol is promising, but it's not quite ready for prime time.